An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland

INTRODUCTION: While most individual primary immunodeficiency diseases (PID) are rare, the collective prevalence of PID results in a substantial economic and clinical burden. The aim of this study was to evaluate the budgetary implications of Ig20Gly (Immune Globulin Subcutaneous [human] 20% solution...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollock, Richard F, Meckley, Lisa M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901127/
https://www.ncbi.nlm.nih.gov/pubmed/29692618
http://dx.doi.org/10.2147/CEOR.S155641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901127/
https://www.ncbi.nlm.nih.gov/pubmed/29692618
http://dx.doi.org/10.2147/CEOR.S155641

Ejemplares similares